Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUVASTATIN SODIUM
B & S Healthcare
20 Milligram
Capsule
2010-07-16
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PPA1328/131/002 Case No: 2077552 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to B & S HEALTHCARE UNIT 4, BRADFIELD ROAD, RUISLIP, MIDDLESEX, HA4 0NU, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product LESCOL 20MG CAPSULES the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 16/07/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 16/07/2010_ _CRN 2077552_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lescol 20mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 20mg Fluvastatin as fluvastatin sodium For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard Capsule _Product imported from the Netherlands_: Capsules are opaque with reddish cap and pale yellow body with XU imprinted on the body of the capsule in red ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lescol is indicated as an adjunct to diet for the reduction of elevated total cholesterol (total-C) and low-density lipoprotein cholesterol (LDL-C), in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types II Read the complete document